@ImmunityBio's Anktiva + BCG Receives EC Conditional Approval for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
#immunitybio #anktiva #conditionalapproval #bcg #nmibc #ec #regulatory #phaseii #phaseiii #quilt3032 #ema
pharmashots.com/31616/immunity…
ImmunityBio’s Anktiva + BCG Receives EC Conditional Approval for BCG-Unresponsive Non-Muscle...
Shots: The EC has granted conditional approval to Anktiva + Bacillus Calmette-Guérin (BCG) to treat BCG-unresponsive NMIBC with CIS, & with/without papillary tumors in all 30 EEA states, based on...
From pharmashots.com 33
